Skip to content
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
Contact
Contact
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
March Biosciences Closes Oversubscribed $28.4 Million Series A Financing
October 23, 2024
8:00 am
Prev
Previous
Cell therapy developed by Baylor scientists shows promise as woman remains cancer-free after 5 years
Next
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Next
Scroll Up